The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate
the health and economic outcomes of lecanemab for early AD. We present the summary of our findings and highlights of the policy discussion with key stakeholders held at a public meeting of the California Technology Assessment Forum (CTAF) on March 17, 2023. The detailed report is available on ICER’s website (https://icer.org/assessment/alzheimers-disease-2022).
